Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Simply click below to discover how you can take advantage of this. UK stock investing: the best FTSE 100 growth share to buy now UK stock investing can be a challenging pastime, especially when it comes to finding growth shares. Indeed, investing in growth stocks can be incredibly risky because trying to forecast how a company will perform in the next few years is virtually impossible. That’s not just limited to growth shares. It’s the same with all investments. However, by focusing on blue-chip FTSE 100 stocks, I believe it’s possible to reduce the risk of investing in growth shares.These large multi-billion-pound companies tend to have more checks and balances in place than smaller firms, which means the risk of something going wrong is significantly reduced. However, it’s always going to be impossible to eliminate the threat.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…With that in mind, here’s one FTSE 100 growth share I’m considering adding to my portfolio today. UK stock investing opportunityHikma Pharmaceuticals (LSE: HIK) is, in my opinion, one of London’s hidden growth stars. The FTSE 100 company is one of the largest producers of generic medicines around the world.These products are vital for healthcare systems worldwide as, without them, treating patients would cost significantly more. When a drug is first launched, it’s protected by a patent for several years. This allows its producer to recoup the development costs and earn a profit.However, other producers, like Hikma, can jump into the market when the drug comes off-patent. It can manufacture and sell treatments for much less than the branded version. In some cases, the discount is 70% or more. This is a huge business, and it’s only likely to grow.But Hikma is always developing new products. It also produced some of the essential drugs used to treat coronavirus patients. Hikma is one of the primary producers of dexamethasone used to treat patients hospitalised with Covid-19. This helped the company to a 6% increase in revenues for 2020. Operating profit jumped 17% to $566m. FTSE 100 growth Of course, operating a business that’s based around the idea of generic versions of others’ products has significant risks. The company is always fighting legal battles, and this is just an extra cost of doing business.It’s also suffered several setbacks whereby regulators have prevented its generic version of a branded product from coming to market. Significant legal battles and substantial product setbacks have impacted the company’s stock price in the past. As long as the corporation is in the business of generic pharmaceuticals, this will continue. Despite these risks, I’d buy the FTSE 100 growth stock for my portfolio today. Healthcare is a growing market. I don’t think that’s going to change.What’s more, affordable healthcare is an increasing issue worldwide, and Hikma is one company policymakers can rely on to produce treatments at affordable prices. However, this could become a risk if those policymakers move in another direction. See all posts by Rupert Hargreaves I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Rupert Hargreaves | Thursday, 25th February, 2021 | More on: HIK Our 6 ‘Best Buys Now’ Shares Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Image source: Getty Images Enter Your Email Address “This Stock Could Be Like Buying Amazon in 1997”
"UK stock investing: the best FTSE 100 growth share to buy now"